Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2021-12-20 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Targeted Alpha Therapy for Bladder Cancer 1st patient dosed 3 pages 217.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX release from Telix Pharmaceuticals Limited announcing the dosing of the first patient in a Phase I clinical study for a targeted alpha therapy candidate for bladder cancer. It provides detailed information about the study, the drug candidate, the collaborating companies, and background on bladder cancer and the company. There are no financial statements, quarterly or annual results, or regulatory certifications. The content is a corporate announcement about a clinical trial milestone, not a financial report, management change, or shareholder meeting material. Therefore, it fits best under the category of a general regulatory announcement or compliance disclosure related to company operations and clinical development progress. Given the absence of a more specific category, the appropriate classification is Regulatory Filings (RNS).
2021-12-20 English
Notification of cessation of securities - TLX 5 pages 27.2KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry and lapse of various options and rights securities of Telix Pharmaceuticals Limited. It provides specific information about the securities that have ceased, reasons for cessation, and the updated issued capital following these changes. There is no indication of financial results, management discussion, or regulatory certifications. The content is focused on changes in the company's issued securities, specifically the cessation of certain securities due to expiry without exercise or conversion. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares or changes in issued securities such as expiry of options or rights. The document is substantive and not merely an announcement of a report, so it is not RPA or RNS. Therefore, the best classification is POS.
2021-12-20 English
FDA Approves Telix Prostate Cancer Imaging Product Illuccix 3 pages 225.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing the FDA approval of Telix Pharmaceuticals' prostate cancer imaging product, Illuccix. It contains detailed product information, safety warnings, and market context but does not include financial statements, management discussion, or regulatory certifications. It is a corporate announcement about a product approval rather than a financial report, earnings release, or regulatory filing. The document length is 9619 characters, which is substantial but the content is clearly a press release about a product approval. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories like earnings, annual report, or management information.
2021-12-19 English
Illuccix EU Regulatory Submission Progress Update 2 pages 205.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX release providing an update on the regulatory submission progress of Telix Pharmaceuticals' product Illuccix in the European Union. It discusses the status of the marketing authorisation application, expected approval timelines, and related regulatory interactions. The document does not contain financial statements, detailed financial performance data, or comprehensive management analysis. It is a regulatory progress update announcement rather than a full report or detailed financial disclosure. The length is 4561 characters, which is relatively short and consistent with a regulatory announcement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-09 English
NUCLIBER - Distribution Agreement for Illuccix in Spain 2 pages 210.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX release announcing a commercial distribution agreement between Telix Pharmaceuticals and NUCLIBER for a prostate cancer imaging product in Spain. It contains no financial statements, no detailed financial performance data, no management discussion of financial results, nor any regulatory filings or certifications. The content is focused on a business development update regarding a distribution agreement. It is not an earnings release, annual report, interim report, or any other financial report. It is also not a regulatory filing or a report publication announcement. The document is best classified as a Capital/Financing Update (CAP) because it relates to a commercial agreement impacting the company's business operations and potential revenue streams, which fits the category of updates on company financing activities or capital structure changes in a broad sense of business development announcements.
2021-12-07 English
Illuccix Granted Use Authorisation in Brazil 2 pages 210.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX release announcing that Telix Pharmaceuticals Limited has received exceptional authorisation from the Brazilian Health Regulatory Agency (Anvisa) to sell their prostate cancer imaging product Illuccix in Brazil. The content focuses on regulatory approval news, product description, market information, and partnership details. It does not contain financial statements, management discussion of financial results, or detailed financial data. The document is a corporate announcement about a regulatory milestone and market access, typical of a Capital/Financing Update or Regulatory Filing. Given the nature of the announcement and the lack of financial data, the best fitting category is Capital/Financing Update (CAP), as it relates to a significant commercial and regulatory development impacting the company's product commercialization and potential revenue streams.
2021-11-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.